3833金沙官网登录|金莎官网3833

HANLIKANG (rituximab injection) is the company's first proprietary product. It is the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guideline for the Development and Evaluation of Biosimilars (Tentative) issued in 2015. As of now, HANLIKANG has been approved by the NMPA for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis for which the originator rituximab has not been approved in China, benefiting a wider patient population with differentiated strategies.

HANQUYOU (trastuzumab, Zercepac^® in Europe，Trade names in Australia: Tuzucip^® and Trastucip^®) was successfully launched in China and Europe, becoming the first Chinese mAb biosimilar entering both the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator. HANQUYOU is certificated by China and the EU GMP. It brings more treatment options to patients with HER2 positive breast and gastric cancer worldwide.

HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It is the only bevacizumab with metastatic colorectal cancer Phase III clinical data in China and proposed to be combined with HANSIZHUANG (PD-1) for immuno-oncology combination therapies to treat various tumors.